Investor Presentaiton
For personal use only
Focus for 2022
Unlocking the value in our pipeline
•
US reimbursement
Tx
Illuccix global rollout
Commercialise diagnostics
Advance core therapeutics
•
Additional global approvals including EU/UK, Canada
Commercial launch from late Q1 2022 (US and AU)
Kidney cancer (TLX250-CDx) Phase III readout
Prepare US regulatory filing for TLX250-CDx
US filing planned for brain cancer imaging product
ProstACT studies active globally
Kidney cancer combination therapy Phase II studies
Initiate Phase II studies in TLX101 and TLX66
[Q84
Pipeline and manufacturing
Seneffe manufacturing / R&D buildout to commence
Focus on strategic deals and in-licensing
Advance early-stage alpha therapy programs
Telix Pharmaceuticals Limited (ASX: TLX)
7
TELIX
PHARMACEUTICALSView entire presentation